Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency
Study Details
Study Description
Brief Summary
The purpose of this study is to show that Protein C Concentrate is a safe and effective treatment for subjects with congenital protein C deficiency. Depending on the type of treatment required, patients are assigned to one of 3 study parts: Part 1 is for the treatment of acute episodes, Part 2 is for short-term prophylaxis, and Part 3 is for long-term prophylaxis in infants aged less than 6 months only.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2/Phase 3 |
Study Design
Outcome Measures
Primary Outcome Measures
- Whether episodes of purpura fulminans, Coumarin-induced skin necrosis and/or other thromboembolic event could be treated effectively, effectively with complications, or not treated effectively with Protein C Concentrate. [Part 1 of the study]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Newborn subjects <= 6 months of age: diagnosis of severe congenital protein C deficiency, with documented functional protein C level < 20%. If a genetic diagnosis is not available prior to initiation of Protein C Concentrate treatment, a documented family history of protein C deficiency is required.
-
Subjects > 6 months of age: confirmed diagnosis of severe congenital protein C deficiency, i.e., by
-
a genetic analysis of severe congenital protein C deficiency (i.e., homozygous or double heterozygous) OR
-
a documented family history of protein C deficiency AND a documented functional protein C level < 20% while the subject is in an asymptomatic state and not receiving oral anticoagulation therapy
-
Signed and dated informed consent from either the subject or the subject's legally authorized representative prior to enrollment. Informed consent includes consent for conducting a genetic analysis (if the genetic defect is unknown).
Exclusion Criteria:
-
Subjects with a history of allergic reactions to Protein C Concentrate. In the case of allergic reactions occurring at the Protein C Concentrate injection site; exclusion from the study is at the discretion of the investigator but should be reported as an AE regardless of the subject's inclusion in or exclusion from the study.
-
Participation in any clinical study in which another investigational agent is used within 30 days prior to enrollment or its use is expected at any time for the duration of study participation.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Los Angeles | California | United States | ||
| 2 | Denver | Colorado | United States | ||
| 3 | Atlanta | Georgia | United States | ||
| 4 | Indianapolis | Indiana | United States | ||
| 5 | Lexington | Kentucky | United States | ||
| 6 | Boston | Massachusetts | United States | ||
| 7 | Cincinnati | Ohio | United States | ||
| 8 | Cleveland | Ohio | United States | ||
| 9 | Dayton | Ohio | United States | ||
| 10 | Fort Worth | Texas | United States | ||
| 11 | Galveston | Texas | United States | ||
| 12 | Houston | Texas | United States |
Sponsors and Collaborators
- Baxalta now part of Shire
Investigators
- Study Director: Study Director, Takeda
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 400101